Proteasome inhibition by bortezomib does not translate into efficacy on two malignant glioma xenografts

Oncology Reports

Volumn 20, Issue 5, 2008, Pages 1283-1287

  Labussiere, Marianne ^a   Pinel, Sophie ^a   Delfortrie, Suzanne ^a   Plenat, François ^a,b   Chastagner, Pascal ^a,c  

^a UNIVERSITÉ DE LORRAINE   (France)

^b CHU NANCY BRABOIS   (France)

^c HÔPITAL D ENFANTS   (France)

Author keywords

Bortezomib; Malignant glioma; Xenograft models

Indexed keywords

BORTEZOMIB; CASPASE 3; CHYMOTRYPSIN; KI 67 ANTIGEN; PROPIDIUM IODIDE; PROTEASOME; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; PYRAZINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG DOSE COMPARISON; DRUG EFFICACY; ENZYME DEGRADATION; FEMALE; FLUOROMETRY; GLIOBLASTOMA; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; INHIBITION KINETICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR XENOGRAFT; ANIMAL; DRUG EFFECT; DRUG SCREENING; GLIOMA; NUDE MOUSE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BORONIC ACIDS; FEMALE; GLIOMA; HUMANS; MICE; MICE, NUDE; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 58149352923     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000142     Document Type: Article

References (21)

1. Stupp R, Mason WP, van den Bent MJ, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996,2005.
2. Ohgaki H and Kleihues P: Epidemiology and etiology of gliomas. Acta Neuropathol 109: 93-108, 2005.
3. Glickman MH and Ciechanover A: The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev 82: 373-428, 2002.
4. Mani A and Gelmann EP: The ubiquitin-proteasome pathway and its role in cancer. J Clin Oncol 23: 4776-4789, 2005.
5. Ludwig H, Khayat D, Giaccone G and Facon T: Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies. Cancer 104: 1794-1807, 2005.
6. Mitsiades CS, Mitsiades N, Hideshima T, Richardson PG and Anderson KC: Proteasome inhibition as a therapeutic strategy for hematologic malignancies. Expert Rev Anticancer Ther 5: 465-476, 2005.
7. Kane RC, Farrell AT, Sridhara R and Pazdur R: United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy. Clin Cancer Res 12: 2955-2960, 2006.
8. Adams J, Palombella VJ, Sausville EA, et al: Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 59: 2615-2622, 1999.
9. Styczynski J, Olszewska-Slonina D, Kolodziej B, Napieraj M and Wysocki M: Activity of bortezomib in glioblastoma. Anticancer Res 26: 4499-4503, 2006.
10. Yin D, Zhou H, Kumagai T, et al: Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastoma multiforme (GBM). Oncogene 24: 344-354, 2005.
11. Chastagner P, Kozin SV and Taghian A: Topotecan selectively enhances the radio response of human small-cell lung carcinoma and glioblastoma multiforme xenografts in nude mice. Int J Radiat Oncol Biol Phys 50: 777-782, 2001.
12. Lightcap ES, McCormack TA, Pien CS, Chau V, Adams J and Elliott PJ: Proteasome inhibition measurements: clinical application. Clin Chem 46: 673-683, 2000.
13. Kremer S, Pinel S, Vedrine PO, et al: Ferumoxtran-10 enhancement in orthotopic xenograft models of human brain tumors: an indirect marker of tumor proliferation? J Neurooncol 83: 111-119, 2007.
14. Adams J, Elliott PJ and Bouchard P: Preclinical development of bortezomib (VELCADET™). In: Proteasome Inhibitors in Cancer Therapy. Adams J (ed). Totowa, NJ, pp233-269, 2004.
15. Dou QP and Li B: Proteasome inhibitors as potential novel anticancer agents. Drug Resist Updat 2: 215-223, 1999.
16. Kitagawa H, Tani E, Ikemoto H, Ozaki I, Nakano A and Omura S: Proteasome inhibitors induce mitochondria-independent apoptosis in human glioma cells. FEBS Lett 443: 181-186, 1999.
17. Wagenknecht B, Hermisson M, Eitel K and Weller M: Proteasome inhibitors induce p53/p21-independent apoptosis in human glioma cells. Cell Physiol Biochem 9: 117-125, 1999.
18. Legnani FG, Pradilla G, Thai QA, et al: Lactacystin exhibits potent anti-tumor activity in an animal model of malignant glioma when administered via controlled-release polymers. J Neurooncol 77: 225-232, 2006.
19. LeBlanc R, Catley LP, Hideshima T, et al: Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res 62: 4996-5000, 2002.
20. Frese KK and Tuveson DA: Maximizing mouse cancer models. Nat Rev Cancer 7: 654-658, 2007.
21. Rich JN: Cancer stem cells in radiation resistance. Cancer Res 67: 8980-8984, 2007.